';

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

Recent Comments

    Recent Posts

    • Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment February 5, 2019
    • 2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record January 15, 2019

    RSS Unknown Feed

    Search

    Tag Cloud

    Agricultural Technology AstraZeneca Bayer Bio-Rad Biopharma Bioproduction Biotech bluebird bio Cancer Immunotherapy Celgene Cell Therapy Chemicals CRO/CMO Diagnostics Drug Development Evolution Global Press Releases Evolution Infographics GE Healthcare Genentech Gene Therapy Genomics & Proteomics GSK Illumina Informatics & Analytics Johnson & Johnson Juno Therapeutics KITE Pharma Life Sciences Lonza Medical Devices Merck Mergers Partnerships & Acquisitions Metagenomics MilliporeSigma Next Generation Sequencing Novartis Pfizer Regenerative Medicine Roche Samsung BioLogics Sanofi Sartorius Stedim Sigma-Aldrich The Future of BioManufacturing Thermo Fisher Scientific

    Text

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. In in lorem sit amet ligula feugiat vulputate vel vitae quam. Cras posuere imperdiet lorem, in aliquam urn

    CategoriesTitle

    • Evolution Infographics
    • News & Analysis

    ArchivesTitle

    • February 2019
    • January 2019
    • October 2018
    • August 2018
    • July 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018
    • October 2017
    • August 2017
    • July 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017
    • January 2017
    • November 2016
    • October 2016
    • September 2016
    • August 2016
    • July 2016
    • June 2016
    • May 2016
    • March 2016
    • February 2016
    • January 2016
    • October 2015
    • September 2015
    • August 2015
    • July 2015
    • June 2015
    • May 2015
    • April 2015
    • March 2015
    • February 2015
    • January 2015
    • November 2014
    • October 2014

    Cat tabs

    First
    Second
    Third
    • Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
      Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
      2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
      2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
      RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
      RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
    • Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
      Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
      2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
      2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
    • Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
      Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
    +44 141 248 2026info@evolution-bio.comNewsletter Sign-UpDownload Our BrochureEvolution Executive Search
    logo
    Evolution Bioscience
    logo
    • Home
    • Clients & Core Services
    • News & Analysis
      • The Future of BioManufacturing
    • IPO Tracker

    Downstream Processing

    The Future of Biomanufacturing: Automated Closed Systems for Cell & Gene Therapy Processes
    The Future of Biomanufacturing: Automated Closed Systems for Cell & Gene Therapy Processes
    More
    Share
    The Future of Biomanufacturing: In Silico Modelling
    The Future of Biomanufacturing: In Silico Modelling
    More
    Share
    The Future of BioManufacturing: Downstream Processing
    The Future of BioManufacturing: Downstream Processing
    More
    Share
    The Future of BioManufacturing
    More
    Share

    Search

    THE FUTURE OF BIOMANUFACTURING

    The Future of BioManufacturing

    Browse By Category

    Agricultural Technology Bioinformatics Biopharma Bioproduction Biotech Cancer Immunotherapy Cell Line Engineering Cell Therapy Chemicals CRO/CMO Diagnostics Downstream Processing Drug Development Gene Therapy Genomics & Proteomics Informatics & Analytics Life Sciences Medical Devices Mergers Partnerships & Acquisitions Metagenomics Modular Factories Molecular Pathology Next Generation Sequencing Regenerative Medicine The Future of BioManufacturing

    Browse By Company

    ACD Bio AstraZeneca Bayer Bio-Rad bluebird bio Celgene Evolution Global Press Releases GE Healthcare Genentech GSK Illumina Johnson & Johnson Juno Therapeutics KITE Pharma Lonza Merck MilliporeSigma Novartis Pfizer Roche Samsung BioLogics Sanofi Sartorius Stedim Sigma-Aldrich Thermo Fisher Scientific

    RECENT POSTS

    Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
    Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
    2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
    2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
    RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
    RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
    Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
    Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
    Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
    Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

    DATA VISUALISATIONS

    Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
    Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
    2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
    2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
    RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
    RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

    About Us

    Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.

    Get In Touch

    +44 141 248 2026

    info@evolution-bio.com

    Recent Posts

    Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
    Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
    2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
    2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
    RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
    RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
    Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
    Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong

    BROWSE NEWS BY INDUSTRY

    Agricultural Technology Biopharma Bioproduction Biotech Cancer Immunotherapy Cell Therapy Chemicals CRO/CMO Diagnostics Drug Development Gene Therapy Genomics & Proteomics Informatics & Analytics Life Sciences Medical Devices Mergers Partnerships & Acquisitions Metagenomics Next Generation Sequencing Regenerative Medicine The Future of BioManufacturing

    BROWSE NEWS BY COMPANY

    Bayer Bio-Rad bluebird bio Celgene Evolution Global Press Releases GE Healthcare Genentech GSK Illumina KITE Pharma Lonza Merck MilliporeSigma Novartis Roche Samsung BioLogics Sanofi Sartorius Stedim Sigma-Aldrich Thermo Fisher Scientific
    2016 © Evolution Bioscience / Darwin Hutton Partners
    Evolution Bioscience